Highest number of cases were in breast; fastest-growing incidence rates were for gastrointestinal cancers<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 18, 2023 (HealthDay News) — From 2010 to 2019, the incidence rates of early-onset cancers increased, with gastrointestinal cancers having the fastest-growing incidence rates, according to a study published online Aug. 16 in JAMA Network Open<\/em>.<\/p>\n Benjamin Koh, from the National University of Singapore, and colleagues characterized patterns in the incidence of early-onset cancers (younger than 50 years) in the United States from 2010 through 2019 in a population-based cohort study including data from 17 National Cancer Institute Surveillance, Epidemiology, and End Results registries. Data were included for 562,145 patients with early-onset cancer; age-standardized incidence rates were extracted per 100,000 people.<\/p>\n The researchers found that the age-standardized incidence rate of early-onset cancers increased overall from 2010 to 2019 (annual percentage change [APC], 0.28 percent) and among women (APC, 0.67 percent) but decreased in men (APC, \u00e2\u0088\u00920.37 percent). In contrast, during the study period, the age-standardized incidence rate of cancers decreased in individuals aged 50 years and older (APC, \u00e2\u0088\u00920.87 percent). The highest number of incident cases of early-onset cancer were in the breast in 2019 (12,649 cases). Among all early-onset cancer groups, gastrointestinal cancers had the fastest-growing incidence rates from 2010 to 2019 (APC, 2.16 percent). The appendix, intrahepatic bile duct, and pancreas had the fastest-growing incidence rates (APCs, 15.61, 8.12, and 2.53 percent, respectively) among gastrointestinal cancers.<\/p>\n “While breast cancer had the highest number of incident cases, gastrointestinal cancers had the fastest-growing incidence rates among all early-onset cancers,” the authors write. “These data may have implications for the development of surveillance strategies and funding priorities.”<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n